{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T20:03:55Z","timestamp":1762113835748,"version":"build-2065373602"},"reference-count":30,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaapos.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of American Association for Pediatric Ophthalmology and Strabismus"],"published-print":{"date-parts":[[2020,6]]},"DOI":"10.1016\/j.jaapos.2020.03.003","type":"journal-article","created":{"date-parts":[[2020,5,24]],"date-time":"2020-05-24T10:27:10Z","timestamp":1590316030000},"page":"149.e1-149.e5","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Late visual outcomes in infants treated with primary bevacizumab for type 1 retinopathy of prematurity"],"prefix":"10.1016","volume":"24","author":[{"given":"Sarah Hilkert","family":"Rodriguez","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sidney A.","family":"Schechet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael J.","family":"Shapiro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael P.","family":"Blair","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaapos.2020.03.003_bib1","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1001\/archopht.121.12.1684","article-title":"Revised indications for the treatment of retinopathy of prematurity: results of the Early Treatment for Retinopathy of Prematurity randomized trial","volume":"121","year":"2003","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.jaapos.2020.03.003_bib2","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1001\/archophthalmol.2010.72","article-title":"Final visual acuity results in the early treatment for retinopathy of prematurity study","volume":"128","author":"Good","year":"2010","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.jaapos.2020.03.003_bib3","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1056\/NEJMoa1007374","article-title":"Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity","volume":"364","author":"Mintz-Hittner","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaapos.2020.03.003_bib4","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1001\/jamaophthalmol.2014.2772","article-title":"Refractive outcomes following bevacizumab monotherapy compared with conventional laser treatment: A randomized clinical trial","volume":"132","author":"Geloneck","year":"2014","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.jaapos.2020.03.003_bib5","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1038\/s41433-018-0151-y","article-title":"UK Retinopathy of Prematurity Special Interest Group. Retinopathy of prematurity in the United Kingdom: retreatment rates, visual and structural 1-year outcomes","volume":"32","author":"Adams","year":"2018","journal-title":"Eye (Lond)"},{"key":"10.1016\/j.jaapos.2020.03.003_bib6","first-page":"365","article-title":"Treatment of type I ROP with intravitreal bevacizumab or laser photocoagulation according to retinal zone","volume":"101","author":"Mueller","year":"2017","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.jaapos.2020.03.003_bib7","first-page":"140","article-title":"Treatment of type 1 retinopathy of prematurity with bevacizumab versus laser","volume":"19","author":"Isaac","year":"2015","journal-title":"J\u00a0AAPOS"},{"key":"10.1016\/j.jaapos.2020.03.003_bib8","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1016\/j.ophtha.2019.03.048","article-title":"Neurodevelopmental outcomes after intravitreal bevacizumab therapy for retinopathy of prematurity: a prospective case-control study","volume":"126","author":"Fan","year":"2019","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jaapos.2020.03.003_bib9","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.3928\/23258160-20161130-03","article-title":"Nonresponse and recurrence of retinopathy of prematurity after intravitreal ranibizumab treatment","volume":"47","author":"Chuluunbat","year":"2016","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"key":"10.1016\/j.jaapos.2020.03.003_bib10","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/j.jcjo.2017.02.012","article-title":"Low-dose ranibizumab as primary treatment of posterior type I retinopathy of prematurity","volume":"52","author":"Ells","year":"2017","journal-title":"Can J Ophthalmol"},{"key":"10.1016\/j.jaapos.2020.03.003_bib11","first-page":"355","article-title":"Bevacizumab compared with diode laser in stage 3 posterior retinopathy of prematurity: A 5 year follow up","volume":"109","author":"O'Keeffe","year":"2016","journal-title":"Ir Med J"},{"key":"10.1016\/j.jaapos.2020.03.003_bib12","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.ajo.2018.05.002","article-title":"Macular structures, optical components, and visual acuity in preschool children after intravitreal bevacizumab or laser treatment","volume":"192","author":"Lee","year":"2018","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.jaapos.2020.03.003_bib13","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.ophtha.2017.08.005","article-title":"Follow-up to age 4 years of treatment of type 1 retinopathy of prematurity intravitreal bevacizumab injection versus laser: fluorescein angiographic findings","volume":"125","author":"Lepore","year":"2018","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jaapos.2020.03.003_bib14","doi-asserted-by":"crossref","first-page":"e70","DOI":"10.1016\/j.ophtha.2018.04.011","article-title":"Re: Lepore et\u00a0al.: Follow-up to age 4 years of treatment of type 1 retinopathy of prematurity intravitreal bevacizumab injection versus laser: fluorescein angiographic findings (Ophthalmology 2018;125:218-26","volume":"125","author":"Blair","year":"2018","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jaapos.2020.03.003_bib15","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1097\/IAE.0000000000001581","article-title":"Prophylactic peripheral laser and fluorescein angiography after bevacizumab for retinopathy of prematurity","volume":"38","author":"Garcia Gonzalez","year":"2018","journal-title":"Retina"},{"key":"10.1016\/j.jaapos.2020.03.003_bib16","first-page":"234","article-title":"Fluorescein angiography to estimate normal peripheral retinal nonperfusion in children","volume":"16","author":"Blair","year":"2012","journal-title":"J\u00a0AAPOS"},{"key":"10.1016\/j.jaapos.2020.03.003_bib17","doi-asserted-by":"crossref","first-page":"280","DOI":"10.3928\/23258160-20160229-12","article-title":"Very late reactivation of retinopathy of prematurity after monotherapy with intravitreal bevacizumab","volume":"47","author":"Snyder","year":"2016","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"key":"10.1016\/j.jaapos.2020.03.003_bib18","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1001\/archopht.1988.01060130517027","article-title":"Multicenter trial of cryotherapy for retinopathy of prematurity: preliminary results","volume":"106","year":"1988","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.jaapos.2020.03.003_bib19","doi-asserted-by":"crossref","first-page":"924","DOI":"10.4103\/ijo.IJO_1078_17","article-title":"Comparison of the efficacy of Lea Symbol chart and Sheridan Gardiner chart for preschool vision screening","volume":"66","author":"Paul","year":"2018","journal-title":"Indian J Ophthalmol"},{"key":"10.1016\/j.jaapos.2020.03.003_bib20","doi-asserted-by":"crossref","first-page":"e20153218","DOI":"10.1542\/peds.2015-3218","article-title":"Canadian Neonatal Network and the Canadian Neonatal Follow-Up Network Investigators. Neurodevelopmental outcomes following bevacizumab injections for retinopathy of prematurity","volume":"137","author":"Morin","year":"2016","journal-title":"Pediatrics"},{"key":"10.1016\/j.jaapos.2020.03.003_bib21","doi-asserted-by":"crossref","first-page":"e74","DOI":"10.1016\/j.ophtha.2017.05.007","article-title":"Ad Hoc Group Concerning Neurodevelopment and antiVEGF. Re: Good: Bevacizumab for retinopathy of prematurity: treatment when pathology is embedded in a normally developing vascular system (Ophthalmology 2016;123:1843-4)","volume":"124","author":"Blair","year":"2017","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jaapos.2020.03.003_bib22","doi-asserted-by":"crossref","first-page":"337","DOI":"10.3928\/23258160-20190605-01","article-title":"Neurodevelopmental outcomes comparing bevacizumab to laser for type 1 ROP","volume":"50","author":"Rodriguez","year":"2019","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"key":"10.1016\/j.jaapos.2020.03.003_bib23","first-page":"61","article-title":"Medical and developmental outcomes of bevacizumab versus laser for retinopathy of prematurity","volume":"22","author":"Kennedy","year":"2018","journal-title":"J\u00a0AAPOS"},{"key":"10.1016\/j.jaapos.2020.03.003_bib24","doi-asserted-by":"crossref","first-page":"e0148019","DOI":"10.1371\/journal.pone.0148019","article-title":"Neurodevelopmental outcomes in infants with retinopathy of prematurity and bevacizumab treatment","volume":"11","author":"Lien","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.jaapos.2020.03.003_bib25","doi-asserted-by":"crossref","first-page":"126","DOI":"10.3928\/23258160-20180129-07","article-title":"Outcomes of intravitreal bevacizumab and diode laser photocoagulation for treatment-warranted retinopathy of prematurity","volume":"49","author":"Chen","year":"2018","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"key":"10.1016\/j.jaapos.2020.03.003_bib26","doi-asserted-by":"crossref","first-page":"255","DOI":"10.3928\/23258160-20170301-10","article-title":"Reactivation of retinopathy of prematurity three years after treatment with bevacizumab","volume":"48","author":"Hajrasouliha","year":"2017","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"key":"10.1016\/j.jaapos.2020.03.003_bib27","first-page":"323","article-title":"Exudative retinopathy and detachment: a late reactivation of retinopathy of prematurity after intravitreal bevacizumab","volume":"17","author":"Ittiara","year":"2013","journal-title":"J\u00a0AAPOS"},{"key":"10.1016\/j.jaapos.2020.03.003_bib28","first-page":"88.e1","article-title":"Refractive outcomes comparing primary laser to primary bevacizumab with delayed laser for type 1 ROP","volume":"23","author":"Anand","year":"2019","journal-title":"J\u00a0AAPOS"},{"key":"10.1016\/j.jaapos.2020.03.003_bib29","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/j.oret.2019.01.016","article-title":"Fluorescein angiography in retinopathy of prematurity: comparison of infants treated with bevacizumab to those with spontaneous regression","volume":"3","author":"Mansukhani","year":"2019","journal-title":"Ophthalmol Retina"},{"key":"10.1016\/j.jaapos.2020.03.003_bib30","doi-asserted-by":"crossref","first-page":"625","DOI":"10.3928\/23258160-20180803-11","article-title":"Late ROP reactivation and retinal detachment in a teenager","volume":"49","author":"Golas","year":"2018","journal-title":"Ophthalmic Surg Lasers Imaging Retina"}],"container-title":["Journal of American Association for Pediatric Ophthalmology and Strabismus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1091853120300938?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1091853120300938?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T20:24:28Z","timestamp":1761078268000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1091853120300938"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6]]},"references-count":30,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,6]]}},"alternative-id":["S1091853120300938"],"URL":"https:\/\/doi.org\/10.1016\/j.jaapos.2020.03.003","relation":{},"ISSN":["1091-8531"],"issn-type":[{"type":"print","value":"1091-8531"}],"subject":[],"published":{"date-parts":[[2020,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Late visual outcomes in infants treated with primary bevacizumab for type 1 retinopathy of prematurity","name":"articletitle","label":"Article Title"},{"value":"Journal of American Association for Pediatric Ophthalmology and Strabismus","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaapos.2020.03.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 American Association for Pediatric Ophthalmology and Strabismus. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}